Merz Pharma Group Declines to Raise Bid for Obagi Medical Products, Inc. (OMPI), Yielding to Valeant Pharmaceuticals International (VRX)
4/8/2013 7:53:27 AM
More...
|
Merz Pharma Group Offers $383.5 Million for Obagi Medical Products, Inc. (OMPI), Tops Deal Announced Last Month With Valeant Pharmaceuticals International (VRX)
4/2/2013 7:32:19 AM
More...
|
Merz Pharma Group Announces Promotion of Hyunna Coelho to Vice President, Commercial Excellence
10/1/2012 11:22:33 AM
More...
|
Merz Pharma Group Announces the Acquisition of CUVPOSA® (glycopyrrolate) Oral Solution, First and Only FDA-Approved Treatment for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions
8/27/2012 10:52:14 AM
More...
|
The Merz Pharma Group Appoints William D. Humphries as New North American Chief Executive Officer
3/14/2012 7:39:19 AM
More...
|
Merz Pharma Group to Complete Acquisition of BioForm Medical, Inc.
2/19/2010 9:54:05 AM
More...
|
Merz Pharma Group Successfully Completes BioForm Medical, Inc. Tender Offer with over 94 Percent of Shares Tendered
2/16/2010 10:11:24 AM
More...
|
Merz Pharma Group Obtains HSR Clearance in Connection with BioForm Medical, Inc. Tender Offer
2/3/2010 10:21:14 AM
More...
|
Merz Pharma Group Commences Tender Offer for All Outstanding Shares of BioForm Medical, Inc.
1/15/2010 11:40:57 AM
More...
|
Merz Pharma Group to Acquire BioForm Medical, Inc. for US $253 Million
1/4/2010 6:29:54 AM
More...
|